Pattern Separation, Brain Derived Neurotrophic Factors, and Mechanisms of Vortioxetine

PHASE4TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

August 24, 2017

Primary Completion Date

August 6, 2018

Study Completion Date

August 6, 2018

Conditions
Depressive DisorderMajor DepressionDepressionDepression, Unipolar
Interventions
DRUG

Vortioxetine

Vortioxetine is a selective serotonin re-uptake inhibitor (SSRI), a common form of treatment for major depressive disorder.

Trial Locations (1)

02114

the Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Takeda

INDUSTRY

lead

Massachusetts General Hospital

OTHER